Company news
ALX Oncology Holdings Inc. news in 2024
ALX Oncology Holdings Inc.'s news releases, calls and decks from 2024, newest first.
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
December 17, 2024
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
December 9, 2024
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
November 13, 2024
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
October 31, 2024
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 8, 2024
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 3, 2024
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 7, 2024
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 5, 2024
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
July 30, 2024
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 1, 2024
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
May 28, 2024
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 6, 2024
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
April 29, 2024
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 23, 2024
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
April 8, 2024
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 6, 2024
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
March 4, 2024
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024